The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Subscribe To Our Newsletter & Stay Updated
